<DOC>
	<DOC>NCT01571453</DOC>
	<brief_summary>This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).</brief_summary>
	<brief_title>Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>The patient suffers from recurrent MDD as the primary diagnosis according to DSMIVTR™ criteria. The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI) The patient has a MADRS total score ≥26 The patient has a CGIS score ≥4 The reported duration of the current MDE is ≥3 months. Other inclusion criteria may apply. The patient meets any of the exclusion criteria listed in the protocol or, in the investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any reason.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>MDD</keyword>
</DOC>